News briefing: Roche shows off more MS, NMOSD data; Galapagos and Gilead clear PhIIa primary endpoints but report SAEs
Roche’s Genentech announced on Friday that it has even more data to back Ocrevus as a multiple sclerosis treatment.
The drug hit the market …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
